Hikma remains constituent of the FTSE4Good Index Series for 5th consecutive year

London, 29 July 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s, stable / BB+ S&P, positive) the multinational generic pharmaceutical company announced today that it remains a constituent of the FTSE4Good Index Series. The FTSE4Good Index Series was created by the global index and data provider FTSE Russell and is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indexes are used by investors to create and assess responsible investment funds and other products.

Press Release Corporate 29 July 2019

text 1

“We are pleased that Hikma has remained in the FTSE4Good Index Series for the fifth straight year,” said Hana Ramadan, head of CSR. “This is a strong acknowledgement of our long-standing commitment to quality, governance and integrity.”

“We have prioritised our activities around five Sustainable Development Goals (SDGs) that most closely align with our business and social engagement strategy: Good Health and Wellbeing, Quality Education, Gender Equality, Decent Work and Economic Growth, Industry, as well as Innovation and Infrastructure,” she added.

For more than a decade, Hikma has been an active member of the UN Global Compact (UNGC), the world’s largest corporate sustainability initiative mobilising companies to do business responsibly by aligning their strategies and operations with principles on human rights, labour, environment and anti-corruption; and to take strategic actions to advance broader societal goals, such as the UN Sustainable Development Goals, with an emphasis on collaboration and innovation.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.